Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$2.0 - $3.28 $1.11 Million - $1.81 Million
-552,690 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$3.14 - $5.15 $8.36 Million - $13.7 Million
-2,661,650 Reduced 82.81%
552,690 $1.74 Million
Q3 2021

Nov 15, 2021

SELL
$4.89 - $7.12 $7.9 Million - $11.5 Million
-1,614,729 Reduced 33.44%
3,214,340 $15.8 Million
Q2 2021

Aug 16, 2021

BUY
$5.65 - $7.47 $7.49 Million - $9.91 Million
1,326,099 Added 37.86%
4,829,069 $32.2 Million
Q1 2021

May 17, 2021

BUY
$5.61 - $12.01 $19.7 Million - $42.1 Million
3,502,970 New
3,502,970 $19.7 Million
Q4 2019

Feb 14, 2020

SELL
$7.99 - $37.6 $6.45 Million - $30.4 Million
-807,727 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$19.17 - $27.4 $2.65 Million - $3.79 Million
138,467 Added 20.69%
807,727 $16.6 Million
Q2 2019

Aug 14, 2019

BUY
$22.93 - $42.84 $6.29 Million - $11.8 Million
274,523 Added 69.55%
669,260 $17.5 Million
Q1 2019

May 15, 2019

BUY
$32.69 - $47.91 $12.9 Million - $18.9 Million
394,737 New
394,737 $15.3 Million
Q3 2018

Nov 14, 2018

SELL
$36.35 - $55.2 $6.5 Million - $9.87 Million
-178,806 Closed
0 $0
Q2 2018

Aug 14, 2018

SELL
$33.85 - $50.65 $3.03 Million - $4.53 Million
-89,368 Reduced 33.32%
178,806 $6.84 Million
Q1 2018

May 15, 2018

SELL
$32.45 - $54.7 $1.51 Million - $2.54 Million
-46,500 Reduced 14.78%
268,174 $10.8 Million
Q4 2017

Feb 14, 2018

SELL
$21.8 - $39.35 $5.78 Million - $10.4 Million
-265,326 Reduced 45.75%
314,674 $11 Million
Q3 2017

Nov 13, 2017

BUY
$16.4 - $25.05 $9.51 Million - $14.5 Million
580,000
580,000 $12.6 Million

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.24B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.